CTLA4 and hypophysitis: Although hypophysitis is reported in 5.6% of patients receiving anti-CTLA4 antibodies and in 0.5%–1.1% of patients receiving anti-PD1 antibodies, hypogonadism is rarely described (Ryder et al., 2014; Barroso-Sousa et al., 2018).